Wockhardt Promethazine With Codeine: Complete Prescribing and Safety Guide

Wockhardt Promethazine With Codeine is a prescription oral solution manufactured by Wockhardt Limited that combines promethazine hydrochloride and codeine phosphate to treat selected severe, non-productive coughs. Classified as a DEA Schedule V controlled substance, it carries FDA Boxed Warnings for addiction, respiratory depression, and dangerous drug interactions with alcohol and other CNS depressants.

Definition: Wockhardt Promethazine With Codeine is a prescription oral solution containing promethazine hydrochloride and codeine phosphate. It is a DEA Schedule V controlled substance used for selected severe, non-productive coughs and carries FDA Boxed Warnings for addiction, respiratory depression, and dangerous drug interactions. It should only be used under direct medical supervision.

Wockhardt Promethazine With Codeine is a prescription oral solution containing 6.25 mg of promethazine hydrochloride and 10 mg of codeine phosphate per 5 mL. Classified as a DEA Schedule V controlled substance, it is prescribed for selected severe, non-productive coughs in appropriately evaluated adults when clinical benefits outweigh the risks. Because it contains an opioid, it carries FDA Boxed Warnings for addiction, respiratory depression, and dangerous drug interactions.

Wockhardt Promethazine With Codeine is a prescription cough medication manufactured by Wockhardt Limited. It combines promethazine hydrochloride — a first-generation phenothiazine antihistamine acting as an H1 histamine receptor antagonist — with codeine phosphate, an opioid antitussive that suppresses the brainstem cough center through mu-opioid receptor agonism.

The oral solution delivers 6.25 mg of promethazine hydrochloride and 10 mg of codeine phosphate per standard 5 mL dose and is classified as a DEA Schedule V controlled substance. It is indicated for the short-term management of selected severe, non-productive coughs when clinical benefit demonstrably outweighs opioid-related risks.

The FDA has issued Boxed Warnings for addiction, misuse, life-threatening respiratory depression, and dangerous interactions with alcohol and central nervous system depressants. Safe use requires precise dosing, pharmacogenetic awareness of CYP2D6 metabolizer status, and direct supervision by a licensed healthcare professional.

What Is Wockhardt Promethazine With Codeine?

Wockhardt Promethazine With Codeine is a prescription oral solution containing promethazine hydrochloride and codeine phosphate. Classified as a DEA Schedule V controlled substance, it is prescribed for selected severe, non-productive coughs and carries FDA Boxed Warnings for addiction, respiratory depression, and dangerous drug interactions.

Manufactured by Wockhardt Limited — a global pharmaceutical company operating under FDA oversight and subject to Current Good Manufacturing Practice (CGMP) regulations — the formulation pairs two pharmacologically distinct agents with complementary but additive CNS-depressant profiles.

Promethazine hydrochloride is a sedating first-generation antihistamine of the phenothiazine class. It functions primarily as an H1 histamine receptor antagonist, producing antihistaminic, sedative, antiemetic, and mild anticholinergic effects. Its sedative properties complement codeine’s central antitussive action while simultaneously amplifying the medication’s CNS depression burden — a pharmacological interaction that defines both its clinical utility and its primary risk profile.

Codeine phosphate is a prodrug metabolized hepatically to morphine via the CYP2D6 enzyme pathway. It suppresses cough by depressing the brainstem cough center through mu-opioid receptor agonism. Patients who are CYP2D6 ultra-rapid metabolizers convert codeine to morphine at accelerated rates, creating disproportionate opioid plasma exposure and substantially elevated toxicity risk — even at standard prescribed doses.

Because it contains a federally controlled opioid, the medication is legally available only with a valid prescription from a licensed healthcare provider. The FDA has issued formal Boxed Warnings for risks including opioid addiction, misuse, life-threatening respiratory depression, and fatal interactions with alcohol and CNS depressants.

This guide provides a clinically grounded reference covering Wockhardt cough syrup ingredients, dosage, pharmacokinetics, drug interactions, contraindications, and comparative context. It is an educational resource and does not substitute for individualized medical evaluation or prescriber guidance.

Wockhardt Cough Syrup Ingredients: Active and Inactive Components

A precise understanding of Wockhardt Promethazine With Codeine’s composition is foundational to evaluating its therapeutic utility and patient-specific risk profile.

Active Ingredients (per 5 mL standard dose)

This concentration — 6.25 mg promethazine hydrochloride and 10 mg codeine phosphate per 5 mL — is the standard formulation for promethazine with codeine oral solutions approved by the FDA and listed in DailyMed, the National Library of Medicine’s official drug labeling database.

Inactive Ingredients

The inactive components may include flavoring agents, preservatives, colorants, and pH stabilizers. While these excipients do not contribute to therapeutic mechanism, they carry clinical relevance for patients with documented allergies or sensitivities to specific dyes, sulfites, parabens, or artificial flavoring compounds.

Prescribers and dispensing pharmacists should review the complete inactive ingredient list for patients with known excipient sensitivities.

Verify the current inactive ingredient list through the dispensing pharmacist or the official DailyMed prescribing information database.

Wockhardt Oral Solution Concentration

The oral solution concentration — 6.25 mg/10 mg per 5 mL — is standardized across FDA-approved promethazine with codeine formulations.

This concentration determines the volume-to-dose relationship critical for accurate administration. A standard adult dose of 5 mL delivers exactly 6.25 mg of promethazine and 10 mg of codeine. Volume measurement precision is a patient safety imperative — not a convenience consideration — in a controlled substance with a documented narrow therapeutic margin.

What Does Wockhardt Prescription Treat?

Wockhardt Promethazine With Codeine is prescribed for the temporary relief of selected severe, non-productive coughs associated with upper respiratory illnesses when the expected clinical benefits outweigh the risks of opioid therapy. It is indicated for a clinically narrow and specifically defined purpose — not for general cough management, mild respiratory symptoms, or any pediatric use.

FDA-Approved Indication

The medication is approved for the temporary relief of selected severe, non-productive (dry) coughs in appropriately evaluated patients where the clinical benefit clearly outweighs the inherent risks of opioid antitussive therapy.

Promethazine’s antihistaminic properties provide supplementary benefit for upper respiratory symptoms such as nasal congestion and mild allergic rhinitis where histamine-mediated pathology contributes to the clinical presentation.

Clinical Contexts Where It May Be Prescribed

• Severe non-productive cough associated with upper respiratory infection causing meaningful functional impairment
• Post-infectious dry cough refractory to non-opioid antitussive therapy
• Cough complicated by concurrent allergic upper respiratory symptoms

When Wockhardt Promethazine With Codeine Is Not Appropriate

The medication is not appropriate for:

• Productive coughs serving a protective airway clearance function
• Children under 12 years of age — absolute contraindication without clinical exception
• Postoperative cough management in pediatric tonsillectomy or adenoidectomy patients
• Patients with documented contraindications to opioid therapy
• Routine management of mild cough associated with the common cold
• Any patient in whom the risks of opioid exposure are not clearly offset by demonstrable clinical benefit

Clinical Perspective: Cough is a physiologically protective mechanism. Suppressing a productive cough with an opioid antitussive may impair mucociliary clearance, prolong respiratory infections, and mask clinically significant lower airway pathology. This medication represents defensible therapy only when the cough is confirmed non-productive, is causing demonstrable distress or functional impairment, and when safer alternatives have been considered and found insufficient.

Promethazine Codeine Schedule V Guidelines: Regulatory Framework

DEA Schedule V Classification

Wockhardt Promethazine With Codeine is federally classified as a DEA Schedule V controlled substance under the Controlled Substances Act. This designation reflects:

• Accepted medical use in the United States with established therapeutic applications
• Lower abuse potential relative to Schedule I through IV controlled substances
• Some potential for physical or psychological dependence — which remains a documented and clinically significant reality despite the comparatively lower scheduling tier

Schedule V classification does not indicate low clinical risk. Codeine dependence, addiction, and overdose deaths occur within Schedule V prescribing contexts. The designation reflects the drug’s relative regulatory position — not an absence of meaningful harm potential at the patient level.

Prescribing and Dispensing Requirements

• A valid prescription from a DEA-registered, licensed prescriber is legally required in all U.S. jurisdictions
• State regulations frequently impose additional dispensing restrictions beyond minimum federal Schedule V standards
• Prescription Drug Monitoring Programs (PDMPs) track Schedule V dispensing across participating pharmacies
• Prescriptions are subject to DEA recordkeeping requirements and state regulatory oversight

Wockhardt Promethazine Codeine Dosage

Dosing for Wockhardt Promethazine With Codeine is individualized based on patient age, body weight, renal and hepatic function, concurrent medications, and overall clinical risk profile. The following parameters represent standard prescribing reference guidance from FDA DailyMed (2025) and do not constitute personalized therapeutic recommendations.

Adult Dosage (Ages 18 and Older)

• Standard dose: 5 mL orally every 4 to 6 hours as needed
• Maximum daily dose: Do not exceed 30 mL in any 24-hour period
• Route: Oral solution; may be taken with or without food

Adolescent Dosage (Ages 12 to 17)

• Standard dose: 2.5 mL to 5 mL orally every 4 to 6 hours as needed
• Maximum daily dose: Do not exceed 30 mL in any 24-hour period
• Prescribing in this age group requires individualized, documented risk-benefit determination by the treating clinician

Pediatric Use (Under Age 12)

Absolutely contraindicated. The FDA has determined that children under 12 face an unacceptable risk of life-threatening respiratory depression from codeine, particularly those who are CYP2D6 ultra-rapid metabolizers. This contraindication is absolute and without clinical exception.

Can Wockhardt Promethazine With Codeine Be Taken With Food?

Yes. The oral solution may be taken with or without food. Administering the dose with food or a full glass of water may reduce nausea in sensitive patients. Food does not meaningfully alter the rate or extent of absorption for either active ingredient at standard therapeutic doses.

Can It Be Taken Before Bed?

Yes — prescribers may schedule evening doses when the sedative properties of promethazine are therapeutically useful for nighttime symptom management.

However, residual sedation frequently persists well into the following morning, impairing cognitive function and driving fitness beyond the period of cough relief. This risk is amplified in elderly patients, those with hepatic impairment, and individuals taking other CNS-active medications.

Patients must not drive or operate machinery the morning following an evening dose until full cognitive recovery is confirmed.

Missed Dose

If a scheduled dose is missed, take it as soon as remembered — unless the next dose is approaching, in which case the missed dose should be skipped entirely.

Never double the dose. Doubling doses of an opioid-containing medication with promethazine’s additive CNS burden creates meaningful risk of excessive sedation, respiratory compromise, and drug accumulation.

Special Population Dosing Considerations

Elderly patients: Increased susceptibility to sedation, falls, respiratory depression, and anticholinergic effects including urinary retention and cognitive impairment. The lowest effective dose with carefully supervised titration is required.

Renal or hepatic impairment: Both active ingredients undergo hepatic metabolism with renal excretion of metabolites. Dose adjustment or alternative therapy should be considered when either organ system is significantly compromised.

CYP2D6 ultra-rapid metabolizers: These patients convert codeine to morphine at rates substantially exceeding population norms, producing disproportionate opioid plasma concentrations at standard doses. According to pharmacogenetic data from the National Library of Medicine’s PharmGKB database, CYP2D6 ultra-rapid metabolizer prevalence ranges from 1% to 29% depending on ethnic ancestry — a range that underscores the clinical importance of pharmacogenetic awareness in prescribing decisions.

Precise Volume Measurement

Every dose must be measured using a calibrated oral dosing syringe — never a household spoon.

Household teaspoons vary in actual volume by 20% to 30%, introducing clinically meaningful dose variability in a controlled substance with a documented narrow therapeutic index. Measurement imprecision is a preventable risk factor for codeine toxicity.

Can Patients Drive While Taking Wockhardt Promethazine With Codeine?

No. Patients must not drive, operate heavy machinery, or engage in any safety-sensitive activity while taking this medication.

Promethazine produces substantial CNS sedation that routinely persists for 4 to 12 hours following a single dose — well beyond codeine’s 4-to-6-hour antitussive window. This sedation impairs reaction time, motor coordination, divided attention, and decision-making capacity at levels functionally comparable to legal alcohol intoxication.

Codeine independently contributes to psychomotor slowing through mu-opioid receptor-mediated CNS depression.

Critically, tolerance to the subjective sensation of drowsiness develops faster than tolerance to measurable psychomotor impairment. A patient who no longer feels drowsy may remain functionally impaired for driving purposes — a pharmacological dissociation with direct and documented road-safety consequences.

Patients, caregivers, and employers must understand that subjective alertness is not a reliable indicator of driving fitness during treatment with this medication.

Wockhardt Syrup Side Effects

All patients initiating Wockhardt Promethazine With Codeine should receive comprehensive counseling on both expected and potentially serious adverse effects before the first dose.

Common Side Effects

These effects occur at therapeutic doses and directly reflect the combined pharmacological properties of both active ingredients:

• Drowsiness and sedation — Most frequent; attributable primarily to promethazine’s CNS-depressant activity
• Dizziness and impaired coordination
• Dry mouth — Anticholinergic effect of promethazine
• Constipation — Opioid-mediated gastrointestinal motility reduction
• Blurred vision
• Nausea and vomiting
• Urinary retention

Can Wockhardt Promethazine With Codeine Cause Constipation?

Yes — and this is among the most predictable adverse effects of codeine-containing medications.

Codeine activates mu-opioid receptors in the enteric nervous system, directly suppressing gastrointestinal motility and increasing intestinal water absorption. The result is slowed intestinal transit that causes constipation in a substantial proportion of patients, even at therapeutic doses and short treatment durations.

Patients should be counseled on adequate hydration, dietary fiber intake, and the appropriateness of stool softeners where clinically indicated.

Extended use carries risk of progressive constipation, obstipation, and opioid-induced bowel dysfunction requiring clinical management.

Serious and Life-Threatening Adverse Effects

The following require immediate emergency evaluation — call 911 without delay:

Clinical Warning: Neuroleptic Malignant Syndrome (NMS) is a rare but potentially fatal reaction associated with phenothiazine-class drugs, including promethazine. It presents as a clinical tetrad of hyperthermia, generalized muscle rigidity, altered consciousness, and autonomic instability. Any clinician observing this constellation must discontinue the drug immediately and initiate emergency management. Early recognition is the primary determinant of patient survival.

Long-Term Use Risks

Sustained use beyond clinically justified short-term intervals introduces compounding and well-characterized risks:

• Physical dependence on codeine — established with consistent use over weeks, even within prescribed dose ranges
• Opioid tolerance — progressive attenuation of antitussive effect requiring escalating doses for equivalent clinical outcomes
• Psychological addiction in genetically and contextually susceptible individuals
• Chronic constipation and opioid-induced bowel dysfunction
• Persistent cognitive effects from sustained CNS depression, particularly in elderly patients

Wockhardt Promethazine With Codeine is not indicated for chronic cough management. A persistent cough beyond the expected resolution of an acute illness warrants formal diagnostic evaluation — not continued antitussive therapy.

Wockhardt Promethazine Codeine FDA Warnings

The FDA’s Boxed Warning — the highest-priority safety communication in U.S. pharmaceutical labeling — appears on all promethazine with codeine prescribing information, including Wockhardt’s formulation. These warnings reflect the FDA’s formal determination that identified risks require the most prominent regulatory alert format available.

Active FDA Boxed Warnings (2025)

1. Addiction, Abuse, and Misuse
Codeine exposes patients and others to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Individual patient risk must be assessed before prescribing, with active monitoring throughout the treatment course.

2. Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with codeine-containing medications — particularly at therapy initiation and following any dose increase. Monitoring for respiratory depression is a clinical requirement, not an optional precaution.

3. Accidental Ingestion
Accidental pediatric ingestion of codeine-containing liquid medications can result in fatal opioid overdose. Secure, locked storage inaccessible to children is a non-negotiable patient safety requirement.

4. Ultra-Rapid Metabolism of Codeine in CYP2D6 Ultra-Rapid Metabolizers
Life-threatening or fatal respiratory depression has occurred in children who received codeine following tonsillectomy or adenoidectomy and were subsequently identified as CYP2D6 ultra-rapid metabolizers. The pediatric contraindication exists precisely because this genetic variation cannot be reliably identified without pharmacogenetic testing.

5. Risks from Concomitant Use with CNS Depressants
Concurrent use with benzodiazepines, alcohol, or other CNS depressants can produce profound sedation, respiratory depression, coma, and death.

Source: FDA DailyMed — promethazine hydrochloride and codeine phosphate oral solution (2025)

The Public Health Context: Promethazine Codeine Misuse

Promethazine with codeine — including Wockhardt’s formulation — is widely recognized in illicit drug culture under the street names “lean,” “purple drank,” or “sizzurp.”

The recreational co-use of promethazine with codeine oral solutions with alcohol, benzodiazepines, or additional opioids has been directly associated with fatal respiratory depression, opioid overdose deaths, and addiction — particularly among adolescents and young adults.

According to the Centers for Disease Control and Prevention (2024), opioid-involved overdose deaths continue to disproportionately affect young adults, with codeine-containing polydrug combinations documented in a clinically significant subset of cases.

This misuse pattern is a primary driver of the FDA’s Boxed Warning framework, the DEA Schedule V classification, and increasingly stringent prescribing and dispensing oversight protocols at both federal and state levels.

What to Tell Your Doctor Before Taking Wockhardt Promethazine With Codeine

The following information is clinically essential for any prescriber evaluating candidacy for this medication. Patients should provide complete, accurate disclosure before therapy begins:

• ☐ Respiratory conditions — Including asthma, COPD, sleep apnea, or any chronic breathing difficulty
• ☐ Liver or kidney disease — Both organs are required for safe drug metabolism and excretion
• ☐ History of substance use disorder — Including alcohol, opioids, benzodiazepines, or any controlled substance
• ☐ Pregnancy or plans to become pregnant — Codeine carries documented fetal risk and neonatal withdrawal consequences
• ☐ Breastfeeding — Codeine and active morphine metabolite transfer into breast milk; infant fatalities are documented
• ☐ Current medications — Including all prescription drugs, over-the-counter products, herbal supplements, and cannabis
• ☐ History of allergic reaction to promethazine, codeine, any opioid, or any phenothiazine-class compound
• ☐ Occupation or activities requiring sustained alertness — Including driving, machinery operation, or patient care responsibilities
• ☐ Prior pharmacogenetic testing identifying CYP2D6 ultra-rapid metabolizer status

Can Wockhardt Promethazine With Codeine Cause a False-Positive Drug Test?

Yes — and this is a clinically and professionally significant consideration for any patient subject to workplace, legal, or clinical drug screening.

Codeine is metabolized to morphine and will produce a positive urine immunoassay result for opioids even when taken as prescribed. Detection windows extend from 1 to 4 days following occasional use and up to 7 days following chronic use.

Additionally, promethazine has been documented in peer-reviewed literature indexed by the National Library of Medicine to produce false-positive results for amphetamines on certain immunoassay platforms, depending on the specific antibody used in the test.

Patients subject to drug testing should proactively disclose their legitimate prescription to the testing administrator before providing a sample.

Confirmatory gas chromatography-mass spectrometry (GC-MS) testing definitively differentiates prescribed codeine metabolites from illicit opioid exposures and resolves promethazine-related immunoassay interference. Patients who fail to disclose a legitimate prescription before a positive result is reported face unnecessary professional and legal consequences that GC-MS confirmation would otherwise prevent.

Wockhardt Cough Syrup Interactions

Drug interactions with Wockhardt Promethazine With Codeine range from clinically significant to immediately life-threatening. Complete medication reconciliation — including all prescription medications, over-the-counter products, herbal supplements, and alcohol — is mandatory before initiating therapy.

Critical Interactions: Contraindicated or Requiring Extreme Caution

Central Nervous System Depressants

Co-administration with any CNS depressant produces additive or synergistic brainstem respiratory suppression — the mechanism underlying the majority of codeine-related polydrug overdose fatalities.

FDA Black Box Warning (2025): Concomitant use of opioids with benzodiazepines or other CNS depressants substantially elevates the risk of respiratory depression, coma, and death. Reserve concurrent prescribing for patients in whom no adequate therapeutic alternative exists. Limit dose and treatment duration to the clinically necessary minimum.

Pharmacokinetic Interactions: CYP2D6 and CYP3A4

Codeine is a primary CYP2D6 substrate; promethazine is metabolized through multiple hepatic cytochrome pathways. Medications that inhibit or induce these enzymes alter drug and metabolite plasma concentrations in clinically meaningful ways:

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion, quinidine): Reduce conversion of codeine to its active morphine metabolite, potentially diminishing antitussive efficacy while altering the adverse effect profile unpredictably
• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): May increase plasma concentrations of promethazine and codeine metabolites, intensifying and prolonging CNS depression
• CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John’s Wort): May reduce drug concentrations below therapeutic thresholds, compromising clinical efficacy

MAO Inhibitors (MAOIs)

Combining promethazine with MAOIs creates risk of serious, potentially fatal adverse reactions including hyperpyrexia, severe cardiovascular instability, and seizures.

Co-administration is absolutely contraindicated. A minimum washout period of 14 days following MAOI discontinuation is required before initiating any promethazine-containing therapy.

Anticholinergic Medications

Promethazine’s inherent anticholinergic activity is additive with other anticholinergic agents, amplifying risk of urinary retention, severe constipation, paralytic ileus, blurred vision, and — particularly in elderly patients — acute anticholinergic delirium.

Alcohol: Mandatory Patient Instruction

Alcohol and promethazine with codeine share overlapping CNS depressant mechanisms. Their combination produces synergistic — not merely additive — respiratory and CNS depression that substantially exceeds what either agent produces independently.

No safe threshold exists for concurrent alcohol use with this medication. Patients must avoid all alcohol-containing products — including over-the-counter preparations, mouthwashes, and herbal products containing ethanol — throughout the complete treatment course.

How Long Does Wockhardt Syrup Stay in Your System?

Wockhardt Promethazine With Codeine usually begins working within 15 to 30 minutes of oral administration. Symptom relief typically lasts 4 to 6 hours per dose, while complete elimination depends on age, liver function, kidney function, genetics, and repeated dosing.

Pharmacokinetic Summary

Drug Detection Windows

Factors That Influence Elimination Duration

• CYP2D6 genotype: Ultra-rapid metabolizers clear codeine faster but produce higher peak morphine concentrations; poor metabolizers experience prolonged parent drug accumulation with reduced therapeutic conversion
• Age: Elderly patients exhibit slower hepatic clearance and extended drug half-lives
• Hepatic and renal function: Impairment in either system prolongs drug and metabolite accumulation
• Concurrent medications: CYP2D6 and CYP3A4 inhibitors extend drug activity; inducers shorten it
• Chronic vs. acute use: Repeated dosing produces accumulation that extends detection windows substantially beyond single-dose estimates

Clinical Note: Promethazine’s sedative duration routinely exceeds codeine’s antitussive window. Patients should anticipate clinically meaningful sedation persisting beyond the period of cough relief — a pharmacokinetic mismatch that is particularly relevant when assessing fitness to drive or perform safety-sensitive tasks.

Wockhardt Promethazine With Codeine vs. Promethazine DM: Key Differences

A clinically important and frequently searched comparison involves Wockhardt Promethazine With Codeine versus Promethazine DM — a formulation that substitutes dextromethorphan (DM) for codeine phosphate as the antitussive agent.

Side-by-Side Comparison

Clinical Perspective: Promethazine DM is the lower-risk alternative for patients requiring antihistamine-antitussive combination therapy when opioid exposure is not clinically justified. However, dextromethorphan is not without its own misuse concerns. At supratherapeutic doses it produces dissociative psychoactive effects, particularly among adolescents. The clinical choice between these formulations requires individualized risk-benefit assessment — not default prescribing.

Promethazine With Codeine Generic vs. Wockhardt: Clinical Equivalence

Regulatory Framework for Generic Approval

All FDA-approved generic promethazine with codeine oral solution products must demonstrate bioequivalence to the reference listed drug. Their rate and extent of active ingredient absorption must fall within FDA-defined equivalence boundaries under standardized pharmacokinetic testing conditions. This standard ensures that approved generics deliver pharmacologically equivalent clinical exposure to Wockhardt’s formulation.

Active Ingredient Identity

FDA-approved generic formulations contain identical active ingredients at identical strengths: 6.25 mg promethazine hydrochloride and 10 mg codeine phosphate per 5 mL. There is no clinically meaningful difference in pharmacological activity, therapeutic efficacy, or safety profile between bioequivalent formulations.

Where Differences May Exist

Differences in inactive ingredients — colorants, flavoring agents, preservatives, and pH stabilizers — are clinically irrelevant for most patients. They become clinically significant only for individuals with documented allergies to specific excipients such as sulfites, parabens, or artificial dyes.

Formulary and Cost Perspective: FDA-approved generic formulations are therapeutically interchangeable with Wockhardt’s product under standard prescribing conditions for patients without relevant excipient sensitivities. Platforms such as GoodRx and RxSaver provide real-time comparative pricing at local pharmacies and can identify meaningful cost savings for patients paying out of pocket.

Contraindications: Who Should Not Receive This Medication

Wockhardt Promethazine With Codeine is contraindicated in specific patient populations where the risk of serious harm is clinically established and not offset by therapeutic benefit.

Absolute Contraindications

• Children under 12 years of age — FDA-prohibited; unacceptable risk of life-threatening respiratory depression without clinical exception
• Postoperative management in pediatric tonsillectomy or adenoidectomy patients — Documented fatal outcomes in CYP2D6 ultra-rapid metabolizing children
• Known hypersensitivity to promethazine, codeine, other opioids, or any phenothiazine-class compound
• Significant existing respiratory depression — Any patient where further suppression is clinically unacceptable
• Acute or severe bronchial asthma — In unmonitored settings or without immediately available resuscitative resources
• Gastrointestinal obstruction — Including paralytic ileus or functional bowel obstruction
• Concurrent MAOI use — Or within 14 days of MAOI discontinuation

High-Risk Populations Requiring Enhanced Clinical Oversight

• Patients with COPD, sleep apnea, or any chronic respiratory compromise
• Elderly patients with baseline cognitive impairment, fall history, or clinical frailty
• Patients with personal or family history of opioid use disorder
• Individuals with documented CYP2D6 ultra-rapid metabolizer genotype
• Pregnant patients — Neonatal opioid withdrawal syndrome is a documented consequence
• Breastfeeding mothers — Codeine and active morphine metabolite transfer through breast milk and can cause fatal respiratory depression in nursing infants

Pregnancy, Breastfeeding, and Reproductive Safety

Pregnancy

Wockhardt Promethazine With Codeine should be avoided during pregnancy whenever clinically possible.

Codeine crosses the placenta, and prolonged use is a recognized cause of Neonatal Opioid Withdrawal Syndrome (NOWS) — requiring specialized neonatal monitoring and management. Promethazine also crosses the placenta and may produce neonatal CNS and respiratory effects following delivery.

Where cough management during pregnancy is clinically necessary, non-opioid alternatives should be exhausted before considering codeine-containing therapy. Any use requires explicit, documented risk-benefit counseling.

Breastfeeding

This medication is contraindicated during breastfeeding.

Codeine and its active morphine metabolite are excreted in human breast milk. In nursing infants — particularly those who inherit a CYP2D6 ultra-rapid metabolizer genotype — even small quantities of morphine transferred through breast milk can cause life-threatening respiratory depression.

Infant fatalities linked to codeine exposure through breast milk are documented in the FDA’s adverse event database and in peer-reviewed literature indexed by the National Library of Medicine. The FDA specifically advises that codeine must not be used by breastfeeding mothers.

Overdose Recognition and Emergency Response

Opioid and combined CNS depressant overdose is a medical emergency with a narrow intervention window. All patients, caregivers, and household members should be prepared to recognize overdose signs and respond without delay.

Signs of Overdose

• Slow, shallow, irregular, or stopped breathing
• Extreme drowsiness or inability to be roused
• Pinpoint pupils unresponsive to light
• Limp muscle tone throughout the body
• Choking or gurgling airway sounds
• Cyanosis — blue or purple discoloration of skin, lips, or fingernails
• Loss of consciousness

Emergency Response Protocol

1. Call 911 immediately — Do not wait to observe whether the person recovers spontaneously
2. Administer naloxone if available — Naloxone (Narcan) rapidly reverses opioid-mediated respiratory depression and is available without a prescription at most U.S. pharmacies
3. Position the patient — Place an unconscious person in the recovery position (on their side) to reduce aspiration risk
4. Stay with the patient until emergency medical services arrive
5. Provide complete medication information to emergency responders — drug name, dose, estimated time of ingestion, and any other substances consumed

Prevention Standard: The CDC recommends that prescribers co-prescribe naloxone for patients receiving opioid-containing medications and ensure both patients and household members receive instruction on proper administration. Naloxone is available through pharmacies and community harm-reduction programs — increasingly without a prescription.

When to Seek Emergency Care

Call 911 immediately if any of the following occur after taking Wockhardt Promethazine With Codeine:

• Breathing that is slow, labored, irregular, or has stopped
• Extreme drowsiness or inability to be roused by voice or physical stimulation
• Pinpoint pupils that do not respond to light changes
• Choking, gurgling, or snoring sounds from the airway
• Cyanosis — blue or gray discoloration of lips, skin, or nail beds
• Seizures
• Signs of severe allergic reaction: throat swelling, difficulty swallowing, or acute urticaria
• Loss of consciousness

Patient Counseling Checklist

Confirm the following safety education at the point of prescribing and dispensing:

• ☐ Do not drink alcohol in any form throughout the full treatment course
• ☐ Do not drive or operate machinery — sedation may persist well beyond the period of cough relief
• ☐ Use only a calibrated oral dosing syringe — never a household spoon
• ☐ Store in a locked, secure location completely inaccessible to children and adolescents
• ☐ Never share this medication — sharing a Schedule V controlled substance is a federal crime
• ☐ Keep naloxone accessible in the household and ensure all members know how to use it
• ☐ Disclose this prescription before any drug testing, surgical procedure, or new medication is prescribed
• ☐ Inform your prescriber of all medications, supplements, herbal products, and cannabis use
• ☐ Dispose of unused medication through a DEA-authorized drug take-back location
• ☐ Contact your prescriber immediately if you experience difficulty breathing, extreme drowsiness, worsening constipation, or any serious adverse effect

Frequently Asked Questions

What is Wockhardt Promethazine With Codeine used for?

Wockhardt Promethazine With Codeine is prescribed for the temporary relief of selected severe, non-productive coughs associated with upper respiratory illnesses when the expected clinical benefits demonstrably outweigh the risks of opioid antitussive therapy. It is not indicated for mild cough, productive cough, or any use in children under 12.

What are the active ingredients in Wockhardt Promethazine With Codeine?

Each standard 5 mL dose contains 6.25 mg of promethazine hydrochloride — a sedating first-generation phenothiazine antihistamine — and 10 mg of codeine phosphate, an opioid cough suppressant that suppresses the brainstem cough center through mu-opioid receptor agonism.

What are the most common Wockhardt syrup side effects?

Common side effects include drowsiness, dizziness, dry mouth, constipation, blurred vision, and nausea. Constipation is particularly predictable due to codeine’s direct suppression of gastrointestinal motility. Serious adverse effects — including respiratory depression or loss of consciousness — require immediate emergency medical attention.

Can Wockhardt Promethazine With Codeine be taken with alcohol?

No. Alcohol and promethazine with codeine produce synergistic — not merely additive — CNS and respiratory depression. Even moderate alcohol consumption concurrent with this medication can precipitate coma or fatal respiratory arrest. No safe threshold exists for concurrent alcohol use during treatment.

Why is Wockhardt Promethazine With Codeine contraindicated in children under 12?

Children under 12 face an unacceptable risk of life-threatening respiratory depression from codeine, particularly those who are CYP2D6 ultra-rapid metabolizers and convert codeine to morphine at accelerated rates. The FDA has determined this risk is absolute — the contraindication admits no clinical exceptions.

How long does Wockhardt syrup stay in your system?

Wockhardt Promethazine With Codeine usually begins working within 15 to 30 minutes. Symptom relief typically lasts 4 to 6 hours, while complete elimination depends on age, liver function, kidney function, CYP2D6 genetics, and repeated dosing. Codeine metabolites are detectable in urine for 1 to 4 days following occasional use and up to 7 days following chronic use. Promethazine’s sedative effects may persist for up to 12 hours — substantially longer than the antitussive window.

What medications interact with Wockhardt Promethazine With Codeine?

Critical interactions include alcohol, benzodiazepines, other opioids, sedative-hypnotics, antipsychotics, muscle relaxants, MAO inhibitors, CYP2D6 inhibitors such as fluoxetine and paroxetine, and CYP3A4 inhibitors and inducers. Each category carries distinct and potentially life-threatening clinical consequences requiring prescriber review before any new agent is added to the patient’s regimen.

Is Wockhardt Promethazine With Codeine the same as generic promethazine with codeine?

FDA-approved generic formulations contain identical active ingredients at identical strengths and must demonstrate bioequivalence to the reference product. Differences in inactive ingredients — including flavoring, colorants, and preservatives — are clinically irrelevant for most patients. Bioequivalent generics are therapeutically interchangeable with Wockhardt’s formulation under standard prescribing conditions.

Can Wockhardt Promethazine With Codeine cause a false-positive drug test?

Yes. Codeine is metabolized to morphine and produces a positive urine immunoassay result for opioids. Promethazine has also been documented to cause false-positive results for amphetamines on certain immunoassay platforms. Patients subject to drug testing should disclose their prescription before providing a sample. Confirmatory GC-MS testing definitively identifies the substances present and resolves immunoassay interference.

Can Wockhardt Promethazine With Codeine be taken with food?

Yes. The oral solution may be taken with or without food. Taking the dose with food or water may reduce nausea in sensitive patients without meaningfully altering drug absorption or bioavailability.

Can it be taken before bed?

Yes — evening dosing may be appropriate when the sedative properties of promethazine are therapeutically useful. However, residual sedation frequently persists into the following morning. Patients must not drive or perform safety-sensitive tasks until full cognitive recovery is confirmed.

Can Wockhardt Promethazine With Codeine cause constipation?

Yes. Constipation is one of the most predictable adverse effects, resulting from codeine’s direct activation of mu-opioid receptors in the enteric nervous system. Adequate hydration, dietary fiber, and stool softeners may help manage this effect. Extended use carries risk of opioid-induced bowel dysfunction requiring clinical intervention.

Safe Storage and Disposal

Storage Requirements

• Store at controlled room temperature (20°C to 25°C / 68°F to 77°F)
• Keep in the original, child-resistant container
• Store in a locked, secure location completely inaccessible to children, adolescents, and individuals at risk for substance misuse
• Do not store in bathrooms, vehicles, or locations subject to heat, humidity, or temperature fluctuation

Disposal

• Preferred: Return unused medication to a DEA-authorized drug take-back location
• Acceptable household disposal: Mix with coffee grounds, dirt, or kitty litter; seal in a bag; discard in household trash — per FDA guidance when take-back is genuinely unavailable
• Do not flush unless the FDA flush list specifically includes the product and take-back is unavailable
• Never share — Sharing a Schedule V controlled substance is a federal crime and a documented pathway to addiction and overdose in the recipient

Conclusion

Wockhardt Promethazine With Codeine occupies a precisely defined and carefully bounded clinical role: the short-term, supervised suppression of certain severe, non-productive coughs in appropriately selected adults when clinical benefits demonstrably outweigh the inherent risks of opioid antitussive therapy.

Its dual active ingredients — promethazine hydrochloride and codeine phosphate — provide complementary antihistaminic and opioid antitussive effects that deliver meaningful relief when safer alternatives have proven insufficient. That relief, however, is inseparable from a risk profile that demands rigorous clinical oversight.

The FDA’s Boxed Warnings for addiction, life-threatening respiratory depression, and dangerous CNS depressant interactions reflect a well-documented pattern of harm when codeine-containing medications are used outside carefully controlled parameters. The absolute pediatric contraindication, the pharmacogenetic complexity of CYP2D6 variability, the documented cultural misuse of promethazine with codeine, the synergistic lethality of alcohol and benzodiazepine co-use, and the breastfeeding prohibition collectively define a medication that requires the highest standard of prescriber vigilance and patient counseling.

For patients who require it, Wockhardt Promethazine With Codeine — administered at the prescribed dose, measured with a calibrated syringe, for the shortest clinically necessary duration, and with complete patient awareness of its interactions and warnings — represents a legitimate and appropriately regulated therapeutic option.

For those who do not require it, the risks are not theoretical. They are precisely characterized, extensively documented, and entirely preventable through evidence-based, patient-centered prescribing.

This article is intended for informational and educational purposes only. It does not constitute medical advice, diagnosis, or individualized treatment guidance. Always consult a licensed healthcare professional before initiating, adjusting, or discontinuing any prescription medication.

Last Updated: 2025 | Primary References: FDA DailyMed (2025) · DEA Controlled Substances Act · CDC Opioid Safety Resources (2024) · National Library of Medicine · PharmGKB CYP2D6 Database · FDA Naloxone Information · DEA Drug Take-Back Program